QCI Interpret for Oncology
Managing multiple biomarker therapeutic development
348 views
In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, QIAGEN QDI will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research.
Interested in learning more?
Click here
Related videos
QCI Interpret for Oncology
Reduce your test turnaround for large cancer panels
Speaker: Sheryl Elkin, CSO, QDI, QIAGEN Interested in learning more? Click here
QCI Interpret for Oncology
Rapid, evidence-based reporting of oncology NGS tests at scale
Competing to offer a comprehensive genomic profiling service for solid or...
QCI Interpret for Oncology
Gaining insights with transcriptomic profiling and mechanistic modeling
In this webinar, Moritz Schütte, head of next-generation sequencing data...
QCI Interpret for Oncology
Going beyond: Molecular evidence for off-label therapy use
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN...